glp 1 and prostate cancer GLP-1 Receptor Agonists: A Promising Therapy for Modern Lifestyle Diseases with Unforeseen Challenges glp-1 prostate cancer Emerging Evidence

The SCALE (Satiety and Clinical Adiposity Liraglutide Evidence) clinical trials evaluating liraglutide 3.0 mg for weight management did not systematically assess sexual function as a primary or secondary outcome, and libido changes were not reported as adverse events of interest

The 17.2 mg tablet delivers the same dose as the 36 mg capsule used in the trial and produces an average weight loss of 11.1% at the approved dose, essentially matching the trial result

GLP-1 curbs appetite and glucose peaks

You might expect GLP-1 users to gradually fade out, drifting off the meds all together

[118] Semaglutide is expected to become patent-free in the United States no earlier than December 2031